First immunochemotherapy outcomes in elderly patients with CLL: A retrospective analysis

Journal of Geriatric Oncology

Volumn 4, Issue 2, 2013, Pages 141-147

  Michallet, Anne Sophie ^a   Cazin, Bruno ^b   Bouvet, Emmanuel ^c   Oberic, Lucie ^c   Schlaifer, Daniel ^d   Mosser, Laurent ^e   Salles, Gilles ^a   Coiffier, Bertrand ^a   Laurent, Guy ^c   Ysebaert, Loïc ^c  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b Huriez University Hospital   (France)

^c CHU PURPAN   (France)

^d Clinique Marzet   (France)

^e Rodez Hospital   (France)

Author keywords

Chemotherapy; CLL; Comorbidity; Elderly

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CYTOPENIA; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 11; COMORBIDITY; CREATININE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RETROSPECTIVE STUDIES; VIDARABINE;

EID: 84875632390     PISSN: 18794068     EISSN: 18794076     Source Type: Journal    
DOI: 10.1016/j.jgo.2013.01.002     Document Type: Article

References (35)

1. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 111:5446-5456.
2. Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2011, 376:1164-1174.
3. Balducci L. ESH-SIOG international conference on haematological malignancies in the elderly. Expert Rev Hematol 2010, 3:675-677.
4. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000, 5:224-237.
5. Lindeman R.D. Changes in renal function with aging. Implications for treatment. Drugs Aging 1992, 2:423-431.
6. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998, 16:1582-1587.
7. Thurmes P., Call T., Slager S., Zent C., Jenkins G., Schwager S., et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008, 49:49-56.
8. Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750-1757.
9. Keating M.J., O'Brien S., Lerner S., Koller C., Beran M., Robertson L.E., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998, 92:1165-1171.
10. Leporrier M., Chevret S., Cazin B., Boudjerra N., Feugier P., Desablens B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98:2319-2325.
11. Eichhorst B.F., Busch R., Hopfinger G., Pasold R., Hensel M., Steinbrecher C., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885-891.
12. Eichhorst B.F., Busch R., Obwandner T., Kuhn-Hallek I., Herschbach P., Hallek M. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. J Clin Oncol 2007, 25:1722-1731.
13. Catovsky D., Richards S., Matutes E., Oscier D., Dyer M.J., Bezares R.F., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230-239.
14. Hillmen P., Skotnicki A.B., Robak T., Jaksic B., Dmoszynska A., Wu J., et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616-5623.
15. Eichhorst B., Hallek M., Dreyling M. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v162-v164.
16. Knauf W. Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2009, 9:165-174.
17. O'Brien S.M., Kantarjian H.M., Cortes J., Beran M., Koller C.A., Giles F.J., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:1414-1420.
18. Flinn I.W., Neuberg D.S., Grever M.R., Dewald G.W., Bennett J.M., Paietta E.M., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007, 25:793-798.
19. Keating M.J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079-4088.
20. Foon K.A., Boyiadzis M., Land S.R., Marks S., Raptis A., Pietragallo L., et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:498-503.
21. Byrd J.C., Peterson B.L., Morrison V.A., Park K., Jacobson R., Hoke E., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003, 101:6-14.
22. Byrd J.C., Rai K., Peterson B.L., Appelbaum F.R., Morrison V.A., Kolitz J.E., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005, 105:49-53.
23. Lin T.S., Donohue K.A., Byrd J.C., Lucas M.S., Hoke E.E., Bengtson E.M., et al. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101. J Clin Oncol 2010, 28:4500-4506.
24. Tam C.S., O'Brien S., Wierda W., Kantarjian H., Wen S., Do K.A., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975-980.
25. Eichhorst B., Goede V., Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009, 50:171-178.
26. Eichhorst B., Dreyling M., Robak T., Montserrat E., Hallek M. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl. 6):vi50-vi54.
27. Abrisqueta P., Pereira A., Rozman C., Aymerich M., Gine E., Moreno C., et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 2009, 114:2044-2050.
28. Brenner H., Gondos A., Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 2008, 111:4916-4921.
29. Piccirillo J.F., Tierney R.M., Costas I., Grove L., Spitznagel E.L. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004, 291:2441-2447.
30. Janssen-Heijnen M.L., van Spronsen D.J., Lemmens V.E., Houterman S., Verheij K.D., Coebergh J.W. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005, 129:597-606.
31. Woyach J.A., Ruppert A.S., Heerema N.A., Peterson B.L., Gribben J.G., Morrison V.A., et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011, 29:1349-1355.
32. Hillmen P. Chronic lymphocytic leukaemia - moving towards cure?. Lancet 2010, 376:1122-1124.
33. Hillmen P., Gribben J.G., Follows G.A., Milligan D., Sayala H.A., Moreton P., et al. Rituximab plus chlorambucil in patients with CD20-positive B-cell chronic lymphocytic leukemia (CLL): final response analysis of an open-label phase II study. Blood 2010, 116(21). [Abstract 697 and oral presentation at: American Society of Hematology Annual Meeting; December 4-7, 2010; Orlando, FL].
34. Foa R., Ciolli S., Di Raimondo F., Del Poeta G., Lauria F., Forconi F., et al. Untreated chronic lymphocytic leukemia: results of the first interim analysis. Blood 2010, 114. [abstract 2462].
35. Fischer K., Cramer P., Busch R., Stilgenbauer S., Bahlo J., Schweighofer C.D., et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011, 29:3559-3566.